Research Papers:
Association of T-cadherin levels with the response to neoadjuvant chemotherapy in locally advanced breast cancer
Metrics: PDF 1386 views | HTML 1638 views | ?
Abstract
Dedi Kong1, Mei-Hong Wang1, Jie Yang2, Liang Li3
1Department of Thyroid and Breast Surgery, Jining No.1 People’s Hospital, Jiningy 272011, Shandong, People’s Republic of China
2Department of Pathology, Jining No.1 People’s Hospital, Jiningy 272011, Shandong, People’s Republic of China
3Department of Pharmacy, Jining No.1 People’s Hospital, Jiningy 272011, Shandong, People’s Republic of China
Correspondence to:
Dedi Kong, email: [email protected]
Keywords: T-cadherin, neoadjuvant chemotherapy, locally advanced breast cancer
Received: September 14, 2016 Accepted: January 07, 2017 Published: January 13, 2017
ABSTRACT
Purpose: To examine the association of T-cadherin with pathologic complete response (pCR) after neoadjuvant chemotherapy for locally advanced breast cancer.
Results: T-cadherin expression before and after neoadjuvant chemotherapy was similar (P = 0.162). The multivariable analysis indicated that negative T-cadherin expression was independently associated with pCR after neoadjuvant TAC chemotherapy (P = 0.001).
Materials and Methods: A total of 136 patients with locally advanced breast cancer received four cycles of neoadjuvant TAC chemotherapy (docetaxel + epirubicin + cyclophosphamide), followed by surgery. T-cadherin, estrogen receptor (ER), progesterone receptor (PR), HER-2, and Ki-67 were analyzed by immunohistochemistry. The association between T-cadherin expression and pCR after neoadjuvant chemotherapy was analyzed using multivariable logistic analysis.
Conclusions: Negative T-cadherin expression before and after neoadjuvant chemotherapy for locally advanced breast cancer was similar. T-cadherin could be considered an independent factor associated with the efficacy of such therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14630